vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and Invivyd, Inc. (IVVD). Click either name above to swap in a different company.
Invivyd, Inc. is the larger business by last-quarter revenue ($17.2M vs $15.0M, roughly 1.1× CHAMPIONS ONCOLOGY, INC.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -64.3%, a 66.1% gap on every dollar of revenue. On growth, Invivyd, Inc. posted the faster year-over-year revenue change (24.5% vs 11.5%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Invivyd, Inc. is a clinical-stage biopharmaceutical company focused on developing broadly neutralizing antibody therapies to prevent and treat serious viral infectious diseases. Its core research and development pipeline targets high-burden respiratory pathogens including respiratory syncytial virus, catering to unmet medical needs of global patient groups.
CSBR vs IVVD — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $17.2M |
| Net Profit | $268.0K | $-11.1M |
| Gross Margin | 51.7% | — |
| Operating Margin | 1.2% | -73.0% |
| Net Margin | 1.8% | -64.3% |
| Revenue YoY | 11.5% | 24.5% |
| Net Profit YoY | -63.2% | 40.0% |
| EPS (diluted) | $0.02 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $17.2M | ||
| Q3 25 | $14.0M | $13.1M | ||
| Q2 25 | $12.4M | $11.8M | ||
| Q1 25 | $17.0M | $11.3M | ||
| Q4 24 | $13.5M | $13.8M | ||
| Q3 24 | $14.1M | $9.3M | ||
| Q2 24 | $14.0M | $2.3M | ||
| Q1 24 | $12.0M | $0 |
| Q4 25 | $268.0K | $-11.1M | ||
| Q3 25 | $-436.0K | $-10.5M | ||
| Q2 25 | $-1.8M | $-14.7M | ||
| Q1 25 | $4.5M | $-16.3M | ||
| Q4 24 | $728.0K | $-18.4M | ||
| Q3 24 | $1.3M | $-60.7M | ||
| Q2 24 | $-109.0K | $-47.2M | ||
| Q1 24 | $-2.5M | $-43.5M |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | -73.0% | ||
| Q3 25 | -3.8% | -84.0% | ||
| Q2 25 | -16.2% | -127.8% | ||
| Q1 25 | 26.4% | -149.7% | ||
| Q4 24 | 5.4% | -139.1% | ||
| Q3 24 | 9.5% | -670.0% | ||
| Q2 24 | -1.9% | -2175.2% | ||
| Q1 24 | -21.4% | — |
| Q4 25 | 1.8% | -64.3% | ||
| Q3 25 | -3.1% | -79.7% | ||
| Q2 25 | -14.9% | -124.4% | ||
| Q1 25 | 26.4% | -144.1% | ||
| Q4 24 | 5.4% | -133.5% | ||
| Q3 24 | 9.3% | -653.1% | ||
| Q2 24 | -0.8% | -2086.9% | ||
| Q1 24 | -21.1% | — |
| Q4 25 | $0.02 | $0.02 | ||
| Q3 25 | $-0.03 | $-0.06 | ||
| Q2 25 | $-0.12 | $-0.12 | ||
| Q1 25 | $0.31 | $-0.14 | ||
| Q4 24 | $0.05 | $-0.14 | ||
| Q3 24 | $0.09 | $-0.51 | ||
| Q2 24 | $-0.01 | $-0.40 | ||
| Q1 24 | $-0.19 | $-0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $226.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $241.5M |
| Total Assets | $30.2M | $276.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $226.7M | ||
| Q3 25 | $10.3M | $85.0M | ||
| Q2 25 | $9.8M | $34.9M | ||
| Q1 25 | $3.2M | $48.1M | ||
| Q4 24 | $2.8M | $69.3M | ||
| Q3 24 | $2.9M | $106.9M | ||
| Q2 24 | $2.6M | $147.9M | ||
| Q1 24 | $4.5M | $189.4M |
| Q4 25 | $4.2M | $241.5M | ||
| Q3 25 | $3.5M | $93.1M | ||
| Q2 25 | $3.8M | $42.8M | ||
| Q1 25 | $5.5M | $54.1M | ||
| Q4 24 | $681.0K | $67.5M | ||
| Q3 24 | $-332.0K | $83.2M | ||
| Q2 24 | $-1.9M | $140.6M | ||
| Q1 24 | $-2.1M | $178.5M |
| Q4 25 | $30.2M | $276.9M | ||
| Q3 25 | $30.5M | $139.2M | ||
| Q2 25 | $32.3M | $89.1M | ||
| Q1 25 | $30.6M | $103.7M | ||
| Q4 24 | $25.2M | $129.5M | ||
| Q3 24 | $24.9M | $161.9M | ||
| Q2 24 | $26.1M | $177.3M | ||
| Q1 24 | $26.8M | $215.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-15.5M |
| Free Cash FlowOCF − Capex | $-2.0M | — |
| FCF MarginFCF / Revenue | -13.1% | — |
| Capex IntensityCapex / Revenue | 1.6% | 0.0% |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $-15.5M | ||
| Q3 25 | $600.0K | $-8.3M | ||
| Q2 25 | $6.9M | $-13.3M | ||
| Q1 25 | $490.0K | $-21.1M | ||
| Q4 24 | $-283.0K | $-37.6M | ||
| Q3 24 | $311.0K | $-41.1M | ||
| Q2 24 | $-1.8M | $-41.6M | ||
| Q1 24 | $-919.0K | $-50.2M |
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $554.0K | — | ||
| Q2 25 | $6.6M | $-13.3M | ||
| Q1 25 | $448.0K | $-21.3M | ||
| Q4 24 | $-377.0K | $-37.6M | ||
| Q3 24 | — | $-41.1M | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-1.0M | $-50.4M |
| Q4 25 | -13.1% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 53.5% | -112.9% | ||
| Q1 25 | 2.6% | -188.2% | ||
| Q4 24 | -2.8% | -272.2% | ||
| Q3 24 | — | -441.6% | ||
| Q2 24 | -13.0% | — | ||
| Q1 24 | -8.4% | — |
| Q4 25 | 1.6% | 0.0% | ||
| Q3 25 | 0.3% | 0.0% | ||
| Q2 25 | 2.0% | 0.1% | ||
| Q1 25 | 0.2% | 1.3% | ||
| Q4 24 | 0.7% | 0.0% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 0.8% | — |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
IVVD
Segment breakdown not available.
